Vertex paused an early-stage trial of its inhaled treatment for cystic fibrosis that came from a partnership with Moderna.

A Singapore-based startup raised a $45 million Series B to start testing a gene therapy in humans next year for a genetic ...

Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

PTC Therapeutics announced Monday that its splicing drug for Huntington’s disease met the primary endpoint of a Phase 2 study ...

Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...

J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new ...

FDA delays Stealth BioTherapeutics PDUFA date amid questions about agency disruption, while other companies like Sanofi and J ...

Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in ...

Topas Therapeutics reveals first data from celiac disease therapy study, showing promise in immune system retraining with ...

Not many would argue that Biotech is one of the riskiest industries on the globe. With costs hovering in the hundreds of millions of dollars, competitors ...

Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...